Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.

Fisher ER, Costantino J, Fisher B, Palekar AS, Paik SM, Suarez CM, Wolmark N.

Cancer. 1996 Oct 1;78(7):1403-16.

2.
3.

Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.

Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, Sigurdson ER, Hoffman JP, Eisenberg BL, Patchefsky A.

Cancer. 2001 May 15;91(10):1862-9.

PMID:
11346867
5.

Lobular carcinoma in situ: observation without surgery as an appropriate therapy.

Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB.

Ann Surg Oncol. 1994 Mar;1(2):141-6.

PMID:
7834439
7.
8.

Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy.

Freedman G, Fowble B, Hanlon A, Nicolaou N, Fein D, Hoffman J, Sigurdson E, Boraas M, Goldstein L.

Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1005-15.

PMID:
10421533
9.

The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.

Fowble B, Hanlon AL, Patchefsky A, Freedman G, Hoffman JP, Sigurdson ER, Goldstein LJ.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):105-15.

PMID:
9747827
10.
12.
13.
14.

Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?

Cutuli B, de Lafontan B, Quetin P, Mery E.

Eur J Cancer. 2005 Feb;41(3):380-5.

PMID:
15691636
15.

Factors predicting in-breast tumor recurrence after breast-conserving surgery.

Mechera R, Viehl CT, Oertli D.

Breast Cancer Res Treat. 2009 Jul;116(1):171-7. doi: 10.1007/s10549-008-0187-y. Epub 2008 Sep 25.

PMID:
18815880
16.

Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.

Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.

Cancer. 2006 Jan 1;106(1):42-50.

17.

Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ.

Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O.

Eur J Surg Oncol. 1991 Feb;17(1):20-9.

PMID:
1847343
18.

Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.

Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ.

Cancer. 2009 Mar 15;115(6):1203-14. doi: 10.1002/cncr.24166. Erratum in: Cancer. 2010 Apr 15;116(8):2064.

19.
20.

Supplemental Content

Support Center